Title: Nanoveson™ therapy; a proposed liquid oral drug therapy utilizing the biological impact properties of lipid remodeling “polymorphism” and lipid membrane self-organization properties “nanobiotechnology” to treat excess liver triglyceride accumulation in fatty liver related diseases utilizing natural compounds.
Subtitle: Liver triglyceride remodeling to phospholipid (lecithin) and release; critical micelle concentration (CMC) level, micellar phase boundary (MPB) and the intestinal formation and elimination of sequestered and aggregated mixed micelles and vesicles (SAMMVs), for treating fatty liver and comorbid diseases and improving enterohepatic circulation and lipid synthesis; with implications for inflammatory diseases including asthma, arthritis, cardiovascular disease and cancer.
By David K. Barker, B.S., M.A., Founder and CEO, ALP Life Sciences, LLC
Copyright © 2009 David K. Barker excluding images
